Stock Down Under

Money-Making Insights On

ASX-Listed Stocks

Recent Articles

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, its never looked back and is more than a one-trick pony!

February 17, 2026

Investors may remember Rhythm Biosciences…

GPT Group (ASX:GPT): Still hasn’t surpassed pre-COVID levels, but is it finally out of the doldrums now?

February 17, 2026

GPT Group (ASX:GPT) released its…

JORC Resources: Here’s What’s Crucial For Investors to Know Before Investing

February 17, 2026

Investors will often hear of…

6 times Takeover Deal regulators hindered a deal involving an ASX Company!

February 17, 2026

Any M&A deal announced where…

Bendigo Bank (ASX:BEN) Beats on Profit but Reveals $90m AUSTRAC Bill- Is This the Risk Income Investors Are Ignoring?

February 17, 2026

Bendigo Bank AUSTRAC Risk: Is…

Qube Holdings (ASX:QUB) Agrees to A$11.7bn Macquarie Takeover- Buy for the Payout or Take Profits Now?

February 17, 2026

Qube Holdings M&A: What the…

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

February 17, 2026

Ansell Shrugs Off Tariffs with…

Aurizon (ASX:AZJ) Surges on 36% Dividend Hike- Buy the Yield or Sell the Rally?

February 17, 2026

Aurizon Dividend Surge: Buy the…

Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors

February 16, 2026

Australian Clinical Labs fell 10%…

Eden Innovations (ASX:EDE) Up 30% on a Debt Free Reset, But Dilution Is the Price

February 16, 2026

$2.2m Loan Converts, Balance Sheet…

Fortif AI (ASX:FTI) The Agentic AI “Data Plane” Behind the Models

February 16, 2026

The Real AI Bottleneck Is…

Magnetic Resources (ASX:MAU) is being acquired by Genesis (ASX:GMD) for $639m! Which ASX gold stocks could be next?

February 16, 2026

Magnetic Resources (ASX:MAU) investors will…

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

February 16, 2026

The Aussie dollar has been…

Banks Smashed It, Healthcare Got Destroyed, Can BHP and Rio Tinto Keep the ASX Rally Alive This Week?

February 16, 2026

Earnings Week: Can BHP and…

St George Mining (ASX:SGQ) Lands 18% Tax Break for Araxá- Is This Rare Earth Explorer a Buy?

February 16, 2026

St George Mining Surges on…

Infratil (ASX:IFT): One of the ASX’s largest infrastructure investors

February 16, 2026

Visit the website of Infratil…

GQG Partners (ASX:GQG) Made Record Profits and the Stock Dropped 27%- Here’s What Investors Are Missing

February 16, 2026

GQG Partners Shares Slide Despite…

ANZ (ASX:ANZ) Hits Record High After Profit Surges 75%, But Is It Too Late to Buy?

February 16, 2026

ANZ Shares Hit Record High…

Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy

February 14, 2026

ASX healthcare stocks are crashing-…

Webjet Group (ASX:WJL) Falls 25% on Failed Takeover and Downgraded Guidance- Value Trap or Hidden Opportunity?

February 14, 2026

Webjet Group Plunges After Takeover…

Find Us in

Stocks Down Under Analysts delve into a large variety of ASX-listed stocks and sectors.

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, its never looked back and is more than a one-trick pony!

By Nick Sundich | February 17, 2026

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no – it’s a…

GPT Group (ASX:GPT): Still hasn’t surpassed pre-COVID levels, but is it finally out of the doldrums now?

By Nick Sundich | February 17, 2026

GPT Group (ASX:GPT) released its annual results (for CY25) yesterday, but the market reaction was nuanced and it remains below pre-COVID levels. Is this company just an undeserved victim of the levels of investor appetite for REITs, or is there something at the fundamental level warranting it to have not reached levels last reached 6…

JORC Resources: Here’s What’s Crucial For Investors to Know Before Investing

By Ujjwal Maheshwari | February 17, 2026

Investors will often hear of JORC Resources or a JORC Code and may think companies are alluding to a mere textbook. It is a strict public reporting standard that governs how mining companies disclose exploration results, Mineral Resources, and Ore Reserves to the market. It exists to protect investors by ensuring statements about a deposit’s…

6 times Takeover Deal regulators hindered a deal involving an ASX Company!

By Nick Sundich | February 17, 2026

Any M&A deal announced where both companies’ boards unanimously back the deal may seem a fait accompli, but takeover deal regulators may have a thing or two to say about the deals. That is why companies say the deals are subject to scruitany, and increasing scruitany under the latest M&A regime. Regulators can block deals…

Bendigo Bank (ASX:BEN) Beats on Profit but Reveals $90m AUSTRAC Bill- Is This the Risk Income Investors Are Ignoring?

By Ujjwal Maheshwari | February 17, 2026

Bendigo Bank AUSTRAC Risk: Is the Yield Worth It? Bendigo and Adelaide Bank (ASX: BEN) fell over 2% on Monday after delivering a half-year result that looked decent on the surface but raised some tough questions underneath. Cash earnings were A$256.4 million for the six months to December 2025, and earnings per share came in…

Qube Holdings (ASX:QUB) Agrees to A$11.7bn Macquarie Takeover- Buy for the Payout or Take Profits Now?

By Ujjwal Maheshwari | February 17, 2026

Qube Holdings M&A: What the Macquarie Bid Means Qube Holdings (ASX: QUB) hit a record high on Monday after signing a binding deal with a Macquarie Asset Management-led consortium at A$5.20 per share, valuing Australia’s largest integrated logistics provider at roughly A$11.7 billion. The offer is a 27.8% premium to Qube’s pre-approach price and marks…

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

By Ujjwal Maheshwari | February 17, 2026

Ansell Shrugs Off Tariffs with Strong Pricing Power Ansell (ASX: ANN) reported half-year results on Monday that told a story most ASX investors weren’t expecting. Revenue barely moved, up just 0.7% to US$1.03 billion, yet adjusted net profit surged 18% to US$95.7 million. The gap between those two numbers reveals something important: this is a…

Aurizon (ASX:AZJ) Surges on 36% Dividend Hike- Buy the Yield or Sell the Rally?

By Ujjwal Maheshwari | February 17, 2026

Aurizon Dividend Surge: Buy the Yield or Wait? Aurizon Holdings (ASX: AZJ) climbed 7 per cent to A$3.84 on Monday after delivering a half-year result that gave income investors exactly what they wanted. The main highlight was a 36 per cent increase in the interim dividend to 12.5 cents per share. This was supported by…

Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors

By Charlie Youlden | February 16, 2026

Australian Clinical Labs fell 10% today after revenue went slightly backwards, even though underlying profit improved. The key nuance is that management deliberately walked away from low margin collection centres and contracts. That decision can pull revenue down in the short term, but it should lift margins and improve the quality of earnings over time.…

Eden Innovations (ASX:EDE) Up 30% on a Debt Free Reset, But Dilution Is the Price

By Charlie Youlden | February 16, 2026

$2.2m Loan Converts, Balance Sheet Clears, Shares Reprice Eden Innovations surged 30% today to 24.5c after announcing it has converted a $2.2m loan into equity for a strategic investor. On top of that, the company said all remaining shareholder loans and unpaid director fees will also be settled in shares, which would leave it debt…

Sector Analysis

The-Best-Mining-Stocks

The Best Mining Stocks

Mining and resources stocks have substantial potential given demand for all types of resources and metals from gold and iron ore to battery metals like lithium and graphite! There are over 700 stocks in this sector from big miners to small cap explorers.

The-Best-Tech-Stocks

The Best Tech Stocks

Tech stocks are appetising in the context of an increasingly digital world ranging from data centre builders, cloud services providers and cybersecurity companies. Many of the ASX's best performing stocks in the last decade have been tech stocks.

The-Best-Uranium-Stocks

The Best Uranium Stocks

Uranium stocks are in a good spot right now with rising demand for clean energy, nuclear energy making a comeback and yellowcake pricing reaching levels not seen since the GFC. This has enabled many companies with mothballed projects to bring them out of hibernation.

Untitled design

The Best Healthcare Stocks

There are dozens of Healthcare stocks on the ASX ranging from big names like CSL and Cochlear with established products and markets, to small cap biotechs and medtechs hoping to follow in their footsteps and commercialise the next big innovation.

The-Best-Mining-Stocks

The Best Mining Stocks

The-Best-Tech-Stocks

The Best Tech Stocks

The-Best-Uranium-Stocks

The Best Uranium Stocks

Share Type Analysis

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The quest for the best stocks to buy now is a never-ending one, but armed with a solid investment strategy, you can create a diversified portfolio that stands the test of time. We provide our Top 10 ASX stocks we think investors should consider right now. 

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The Top Penny Stocks

The Top Penny Stocks

Navigating ASX Penny stocks, can be complex, given the diversity of companies operating in various sectors and the high risk associated with them. But there is potential for impressive returns if investors can find the right company.

The Top Penny Stocks

The Top Penny Stocks

The Top Dividend Stocks

The Top Dividend Stocks

Investing in Dividend stocks can provide an additional source of income, and so are popular with a wide variety of investors. But only some companies pay dividends, and even consistent payers can fluctuate payouts year to year. We outline the Top Dividend Stocks for investors to consider.

The Top Dividend Stocks

The Top Dividend Stocks

size set 1

Top ASX Index Funds

Explore our comprehensive analysis of the top ASX index funds, carefully curated by industry experts. Discover which funds are currently outperforming and why, based on detailed market trends and performance metrics. Ideal for both new and seasoned investors seeking strategic investment opportunities on the ASX. Dive into our report today to make informed investment decisions.

size set 1

Top ASX Index Funds

size 2

The Top Blue Chip Stocks

Discover the best ASX blue chip stocks for investment. Our industry experts provide in-depth analysis on these well-established companies with strong credit ratings and a long history of performance and stability. Explore market leaders like Commonwealth Bank of Australia, BHP Group Ltd, and National Australia Bank Limited.

size 2

The Top Blue Chip Stocks

size 3

Top ASX Growth Stocks for Investing

Explore our comprehensive analysis of the top ASX growth stocks for investing. Our industry experts have curated a detailed report on the most promising opportunities available in the market. Whether you're a seasoned investor or just starting out, our insights provide valuable information to help you make informed decisions.

size 3

Top ASX Growth Stocks for Investing

Webinars and Interviews

DorsaVi (ASX:DVL) unveiled its ambitious 22nm ReRAM strategy: Interview with Group CEO Mathew Regan

DorsaVi (ASX:DVL) is switching into high gear We spoke to DorsaVi’s Group CEO, Mat Regan, about…

Unicycive Therapeutics (Nasdaq:UNCY) has big plans for its lead candidate OLC

Unicycive Therapeutics (Nasdaq:UNCY) Unicycive Therapeutics is a clinical-stage biotech company based in Los Altos, CA. The…

Weebit Nano signs license deal with Texas Instruments: Interview with CEO Coby Hanoch

Weebit Nano bags an analog elephant We spoke with CEO Coby Hanoch about the license deal…

Chimeric Therapeutics (ASX:CHM) is headed for the CAR-T ‘Big Time’

Chimeric Therapeutics (ASX:CHM) We spoke to Dr Rebecca McQualter, CEO of Chimeric Therapeutics (ASX:CHM), about the…

Investment Glossary

What Is a Small Cap Company? A Complete Guide for Investors

September 24, 2024

Overview of Small Cap Companies…

What is the All Ordinaries Index and How Does It Work?

September 20, 2024

The All Ordinaries Index, also…

What is Commodity? Understanding Commodity Trading

May 23, 2024

Introduction to Commodities Commodities are…

Overview of Securities in the Australian Financial Market

May 23, 2024

What is a security? Security refers…

What Is an IPO? Understanding Initial Public Offerings

May 23, 2024

What is IPO? An Initial Public…

The Team Behind Stocks Down Under

1rw

Stuart Roberts

Co-Founder

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research

Marc-circle-300x300_webp

Marc Kennis

Co-Founder

Marc is the co-founder of Stocks Down Under and has 25+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research,

The Team Behind Stocks Down Under

STUART ROBERTS

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research together with Marc.

MARC KENNIS

Marc is the co-founder of Stocks Down Under and has 20+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research, Australia's preeminent issuer-sponsored equities research firm.

PETER KILBY

Pete is Stocks Down Under's head of customer service. He is an avid investor with a knack for deep-dive company research. Pete likes the more established companies on ASX, but doesn't shy away from the occasional risky play. At Stocks Down Under he gets to do the two things he loves most, investing and talking to like-minded people.

Please enter your name.
Please enter a message.